Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1–skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen.
Article activity feed
-
-
-
SciScore for 10.1101/2020.11.17.368258: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Animal experiment approval was provided by the Institutional Animal Care and Use Committee (IACUC) at CRL Montreal ULC, Laval Site (CA). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Adult NHP: 60 (57 females and 3 males. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Clinical isolate SARS-CoV-2/human/NLD/Leiden-0008/2020 (Leiden-0008) was isolated from a RT-PCR positive throat swab and passaged twice in Vero E6 cells. Vero E6suggested: RRID:CVCL_XD71)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An …SciScore for 10.1101/2020.11.17.368258: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Animal experiment approval was provided by the Institutional Animal Care and Use Committee (IACUC) at CRL Montreal ULC, Laval Site (CA). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Adult NHP: 60 (57 females and 3 males. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Clinical isolate SARS-CoV-2/human/NLD/Leiden-0008/2020 (Leiden-0008) was isolated from a RT-PCR positive throat swab and passaged twice in Vero E6 cells. Vero E6suggested: RRID:CVCL_XD71)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04505722 Active, not recruiting A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Medi… NCT04614948 Recruiting A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-medi… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-